(2-(5-amino-pyridin-2-yloxy)-ethyl)-propyl-carbamic acid tert-butyl ester | 403741-01-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (2-(5-amino-pyridin-2-yloxy)-ethyl)-propyl-carbamic acid tert-butyl ester
• 英文别名: 1,1-Dimethylethyl N-[2-[(5-amino-2-pyridinyl)oxy]ethyl]-N-propylcarbamate；tert-butyl N-[2-(5-aminopyridin-2-yl)oxyethyl]-N-propylcarbamate
• CAS: 403741-01-5
• 化学式: C₁₅H₂₅N₃O₃
• 分子量: 295.382
• InChiKey: CDCOJNYXSSEXRO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  77.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[3-(dimethylamino)propyl]-3-ethylcarbondiimide hydrochloride 、 4-oxo-4,5,6,7,4-tetrahydro-1H-indazole-3-carboxylic acid 、 (2-(5-amino-pyridin-2-yloxy)-ethyl)-propyl-carbamic acid tert-butyl ester 生成 4-oxo-4,5,6,7-tetrahydro-1H-indazole-3-carboxylic acid [6-(2-propylamino-ethoxy)-pyridin-3-yl]-amide
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Substituted fused pyrroleoximes and fused pyrazoleoximes
  申请人：——

  公开号：US20020128236A1

  公开（公告）日：2002-09-12

  Disclosed are compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  揭示了公式1的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2在此处定义。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或逆拮抗剂，或者是GABAA脑受体的激动剂、拮抗剂或逆拮抗剂的前药，因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆的诊断和治疗中非常有用。还披露了包括包装的药物组合物在内的药物组合物。
• Novel aryl substituted tetrahydroindazoles as ligands of the GABA receptor
  申请人：——

  公开号：US20020055524A1

  公开（公告）日：2002-05-09

  Disclosed are compounds of the formula 1 and the pharmaceutically acceptable salts thereof wherein the variables R 1 , R 2 , R 3 , n, and Ar are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory.

  揭示了公式1的化合物及其药用盐，其中变量R1、R2、R3、n和Ar在此处定义。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAA脑受体的激动剂、拮抗剂或反向激动剂的前药，因此在焦虑、抑郁、唐氏综合症、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆的诊断和治疗中具有用途。
• Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes
  申请人：Maynard George

  公开号：US20080032975A1

  公开（公告）日：2008-02-07

  Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  本发明涉及以下式的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2的定义如下。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药，因此可用于诊断和治疗焦虑症、抑郁症、唐氏综合征、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆。还公开了包括包装的药物组合物在内的制药组合物。
• ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR
  申请人：Grandel Roland

  公开号：US20090143383A1

  公开（公告）日：2009-06-04

  The present invention relates to aryloxyethylamine compounds of the formula I and the physiologically tolerated acid addition salts thereof. The variables have the meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及公式I的芳氧乙胺化合物及其生理耐受的酸盐。变量的含义如权利要求书和说明书中所述。本发明还涉及使用公式I的化合物或其药学上可接受的盐制备用于治疗对多巴胺D3受体配体敏感的医疗疾病的药物组合物。
• ARYL SUBSTITUTED TETRAHYDROINDAZOLES AND THEIR USE AS LIGANDS FOR THE GABA-A RECEPTOR
  申请人：NEUROGEN CORPORATION

  公开号：EP1315703A1

  公开（公告）日：2003-06-04